
5 Things to Watch at SABCS 2026
Key Takeaways
- Extended NATALEE follow-up with ribociclib plus endocrine therapy may clarify absolute benefit by nodal burden, informing risk-adapted adjuvant CDK4/6 inhibitor use in HR+/HER2− early disease.
- First clinical readouts for RAE346 target mutant PI3Kα, reinforcing ongoing therapeutic innovation in the PI3K pathway amid an increasingly crowded and regulatory-active HR+ metastatic landscape.
Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.
The San Antonio Breast Cancer Symposium (SABCS), the world's largest meeting focused on breast cancer, runs Dec. 8-11 in San Antonio, Texas. More than 11,000 doctors, researchers and patient advocates from over 100 countries are expected, and organizers received a record 2,324 abstract submissions this year. Press conferences on the most newsworthy findings are scheduled for Dec. 9, 10 and 11.
Many results won't be public until they're presented. But company announcements and early previews point to several themes worth watching. Here are five.
1. Six Years of Kisqali Data in Early Breast Cancer
Cancer type: Hormone receptor (HR)-positive, HER2-negative early breast cancer
Novartis will present a six-year analysis of the NATALEE trial of Kisqali (ribociclib) as a late-breaking abstract. The analysis looks at outcomes by nodal status, meaning whether and how much the cancer had spread to nearby lymph nodes. Longer follow-up helps patients and doctors understand who benefits most from adding Kisqali to hormone therapy after surgery.
2. First Results for a New Targeted Pill, RAE346
Cancer type: HR-positive, HER2-negative breast cancer
Novartis' second late-breaking abstract will share the first clinical data from a phase 1/2 study of RAE346, formerly called SNV4818. It is designed to target mutated forms of a protein called PI3K-alpha, which can drive the growth of some HR-positive breast cancers. This is an early study, but drugs that target the PI3K pathway are an active area in breast cancer, with
3. Blood Tests That Guide Treatment
Blood tests that look for tumor DNA, often called circulating tumor DNA or ctDNA, are changing how some breast cancers are treated. The phase 3 SERENA-6 trial showed a benefit from switching hormone therapy to camizestrant when a blood test detected an ESR1 mutation, before scans showed the cancer growing. Camizestrant, now sold as Etcamah, was
At SABCS, researchers will also present posters on tests designed to detect tiny amounts of cancer left after treatment, known as minimal residual disease. Watch for how these tests may one day help decide who needs more treatment and who may safely need less.
4. How AI Is Entering Breast Cancer Care
According to a meeting preview by a consultant breast surgeon writing for Oncology Central, an important part of this year's meeting will be discussion of how artificial intelligence (AI) is being built into medicine, including diagnosis, treatment decisions and risk assessment. For patients, key questions include how accurate these tools are, how they're tested and how they fit alongside a doctor's judgment.
5. A Vaccine Being Tested to Prevent Recurrence
Greenwich LifeSciences will present two posters on Dec. 9 related to FLAMINGO-01, an ongoing phase 3 trial of GLSI-100, an immunotherapy designed to help prevent breast cancer from coming back. The posters were written by the trial's steering committee. Because the trial is still underway, these presentations are not expected to answer whether the vaccine works, but they offer a look at an approach many patients ask about.
What Should Patients Do With This Information?
Meeting previews only tell part of the story. Full results, including how much a treatment helped and what side effects people had, will come out during SABCS. If you have breast cancer, ask your care team whether any of these findings or a related clinical trial could apply to you, and follow CURE's SABCS 2026 coverage for updates.
References
- Reserve housing and register today: San Antonio Breast Cancer Symposium 2026, December 8-11. American Association for Cancer Research. Accessed Nov. 18, 2026.
https://www.aacr.org/about-the-aacr/newsroom/media-advisories/reserve-housing-and-register-today-san-antonio-breast-cancer-symposium-2026-december-8-11/ - SABCS 2026: 49th Annual San Antonio Breast Cancer Symposium. OncoDaily. Accessed Nov. 18, 2026.
https://oncodaily.com/event/sabcs-562348/ - Benson J. Key presentations to bookmark at SABCS 2026. Oncology Central. Nov. 18, 2026. Accessed Nov. 18, 2026.
https://www.oncology-central.com/key-presentations-to-bookmark-at-sabcs-2026/ - Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS. Novartis, via GlobeNewswire. Nov. 18, 2026. Accessed Nov. 18, 2026.
https://www.globenewswire.com/news-release/2026/11/18/3405374/0/en/novartis-showcases-hematology-momentum-and-continued-breast-cancer-leadership-at-ash-and-sabcs.html - Meet us at San Antonio Breast Cancer Symposium 2026. Haystack MRD, Quest Diagnostics. Accessed Nov. 18, 2026.
https://haystackmrd.com/sabcs-2026/ - Greenwich LifeSciences announces acceptance of abstracts at SABCS 2026. Greenwich LifeSciences, via BioSpace. Nov. 17, 2026. Accessed Nov. 18, 2026.
https://www.biospace.com/press-releases/greenwich-lifesciences-announces-acceptance-of-abstracts-at-sabcs-2026 - FDA approves Etcamah plus CDK4/6 inhibitor for ESR1-mutated breast cancer. CURE. Sept. 4, 2026.
https://www.curetoday.com/view/fda-grants-accelerated-approval-to-new-breast-cancer-treatment-for-patients-with-esr1-mutations
For more news on cancer updates, research and education,
Related to this article








